06:21 AM EDT, 06/16/2025 (MT Newswires) -- Sarepta Therapeutics ( SRPT ) shares were down 37% in recent premarket activity Monday, a day after the company said it's temporarily suspending shipments of Elevidys for non-ambulatory patients with Duchenne muscular dystrophy following a second reported case of acute liver failure resulting in death.

The company said Sunday that the shipments will remain suspended while an "enhanced" immunosuppressive regimen is assessed, discussed with regulatory bodies, and put in place.

Sarepta also said it has voluntarily paused dosing in a clinical study of Elevidys in older ambulatory and non-ambulatory individuals living with Duchenne muscular dystrophy, a severe genetic disorder characterized by progressive muscle degeneration and weakness.